Replies to post #67966 on Biotech Values

[rkrw]

I think you may as well put avrx in there. Goes to show even a highly distressed sale may be able to salvage a premium.

I just remembered, gnlb has a deal with GSK for an HEV vaccine. That could have helped justify the premium---pv on the future royalty.